InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387
NanoViricides, Inc. (NYSE American: NNVC) provided an update on its Measles drug development program, highlighting the potential of its broad-spectrum antiviral candidate NV-387. With declining vaccination rates raising the risk of measles becoming endemic in the United States, the company emphasized the need for an effective antiviral treatment. NV-387, which has shown success against related viruses like RSV in animal models, is being prepared for…